Abstracts tagged "SLE"

Abstract Number: 859 • 2014 ACR/ARHP Annual Meeting
TGF-β3-Producing CD4⁺CD25^–LAG3⁺ Regulatory T Cells Control B Cell Responses
Tomohisa Okamura¹, Kaoru Morita¹, Mariko Inoue¹, Toshihiko Komai¹, Yukiko Iwasaki¹, Shuji Sumitomo¹, Shinichiro Nakachi¹, Hirofumi Shoda², Keishi Fujio² and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and associated with a wide range of clinical manifestations. Recent case-control association…
Abstract Number: 636 • 2014 ACR/ARHP Annual Meeting
Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE
Yaakov Naparstek¹, Eli Moallem², Rina Ulmansky³, Erez Koren³ and Yechezkel Barenholz³, ¹Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ²Dept. of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ³Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Background/Purpose Glucocorticoids (GCs) have been known for years to be the most effective therapy in SLE. Their use is however limited by the need of…
Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Taher Fatakdawala¹, Michael Skawinski¹, Jonathan Ferriera², Tara Stauffer¹ and Thomas Lavoie¹, ¹Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, ²Quality Control, PBL Assay Science, Piscataway, NJ
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
Abstract Number: 1600 • 2013 ACR/ARHP Annual Meeting
Anti-Ribosomal P Protein Antibodies Exacerbate Long-Term Prognosis In Patients With Diffuse Neuropsychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematous
Yoshiyuki Arinuma¹, Hirotoshi Kikuchi², Eisuke Ogawa¹, Tatsuhiko Wada¹, Tatsuo Nagai³, Sumiaki Tanaka¹ and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Systemic lupus erythematous (SLE) is a chronic inflammatory disease characterized by the expression of a variety of autoantibodies. Although the comprehensive survival from the…
Abstract Number: 646 • 2013 ACR/ARHP Annual Meeting
Expression Of Interferon-Inducible Gene (Lymphocyte Antigen 6 Complex Locus E) In Systemic Lupus Erythematosus Patients and Its Association With Disease Activity
Eman Omran¹, Tayseer M Khidre², Eman Alkady³, Eman Mosaad⁴ and Mona Hussein Abd Elsamea³, ¹Rheumatology and Clincal Immunology, Assiut University- Faulty of Medicne, Assiut, Egypt, ²Assiut University, Faculty of Medicine, Assiut, Egypt, ³Assiut University- Faculty of Medicine, Assiut, Egypt, ⁴AssiutUniversity- Faculty of Medicine, Assiut, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation resulting in the production of antinuclear and other autoantibodies, generation of…
Abstract Number: 540 • 2013 ACR/ARHP Annual Meeting
Exploration Of a Novel Therapeutic Target In a Murine Model Of Systemic Lupus Erythematosus: Targeting Sphingosine-1-Phosphate (S1P) Receptors
Christopher Tracy¹, Jess Edison², S. Frattalone² and C. Moratz³, ¹Internal Medicine-Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ³Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by symptomatic flares that often result in terminal organ failure. The pathogenesis is characterized by…
Abstract Number: 2891 • 2013 ACR/ARHP Annual Meeting
Loss Of Caspase 8 Exacerbates Dendritic Cell Activation In a MyD88- and RIPK1-Dependent Manner That Is Controlled By Inhibitory Molecules Transcribed By IRF3
Carla M. Cuda¹, Alexander V. Misharin², Rana Saber² and Harris R. Perlman³, ¹Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine/Rheumatology, Northwestern University, Chicago, IL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE). While DCs from SLE patients exhibit elevated activation,…
Abstract Number: 1765 • 2013 ACR/ARHP Annual Meeting
Complement Component C5a Permits The Co-Existence Of Pathogenic Th17 Cells and Type I Interferon In Lupus
Marc C. Levesque¹, Sudesh Pawaria², Kelly Maers² and Partha Biswas³, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Dept. of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a type I interferon (IFN-I)-driven autoimmune disorder with exaggerated B and T-helper (Th) cell responses. Th17 cells, a recently…
Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Lucy M. Carter¹, David A. Isenberg² and Michael R. Ehrenstein³, ¹University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…
Abstract Number: 630 • 2013 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Highly Increased On Circulating Microparticles In SLE Patients and Co-Localizes With IgG In Glomerular Deposits In Human Lupus Nephritis
Christoffer T. Nielsen^1,2, Ole Østergaard³, Ole Petter Rekvig⁴, Gunnar K. Sturfelt⁵, Søren Jacobsen⁶ and Niels H. H. Heegaard⁷, ¹Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Infectious Diseases and Rheumatology, University Hospital Rigshospitalet, Copenhagen, Denmark, ³Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, ⁴Department of Biochemistry and Medical Biology, University Hospital, Tromsø, Norway, ⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ⁶Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁷Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: The origin of autoantigens in glomerular immune complex (IC) deposits in lupus nephritis patients is unknown. They may derive from the circulation (microparticle (MP)-ICs…
Abstract Number: 41 • 2013 ACR/ARHP Annual Meeting
Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity
Peter Schafer¹, Emily Rychak², Derek Mendy³, Stacey Parton¹, Lori Capone⁴, Antonia Lopez-Girona², Dorota Cedzik⁵, Jolanta Kosek⁵, Ling-Hua Zhang⁵ and Rajesh Chopra⁵, ¹Department of Translational Development, Celgene Corporation, Summit, NJ, ²Molecular & Medical Science, Celgene Signal Research, San Diego, CA, ³Celgene Signal Research, San Diego, CA, ⁴Celgene Corporation, Summit, NJ, ⁵Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex including CUL4A, DDB1, and ROC-1. CC-220 is a novel immunomodulatory compound currently in…
Abstract Number: 2894 • 2013 ACR/ARHP Annual Meeting
Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus
Laurie Davis¹, Yong Du², Tianfu Wu³ and Chandra Mohan⁴, ¹Internal Medicine, UT Southwestern Medical Center, Dallas, TX, ²Internal Medicine - Rheumatic Diseases, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ³Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ⁴University of Houston, Houston, TX
Background/Purpose: In healthy individuals, TREM-1 proteins are cell surface receptors expressed by hematopoietic cells of the myeloid lineage. TREM-1 is a potent amplifier of proinflammatory…
Abstract Number: 1699 • 2013 ACR/ARHP Annual Meeting
Development Of Systemic Lupus Erythamatosus Among “Possible Systemic Lupus Erythamatosus ” Patients Seen In Consultation: Long-Term Follow-Up
May Al Daabil¹, Bonnie L. Bermas¹, Tabatha Norton¹, Hsun Tsao¹, Patricia Ho¹, Joseph F. Merola¹, Peter H. Schur¹, Elena M. Massarotti¹ and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatology consultation to rule out SLE is common. However, in a substantial proportion of patients, SLE can be neither confirmed nor ruled out at…
Abstract Number: 1567 • 2013 ACR/ARHP Annual Meeting
Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study
Yasuhiro Suyama¹, Mitsumasa Kishimoto¹, Hiroto Nakano², Chisun Min³, Yoichiro Haji¹, Ryo Rokutanda¹, Yuri Ohara¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi⁴, Yukio Matsui⁴, Kazuo Matsui² and Masato Okada⁴, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ³Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: A high incidence of trimethoprin-sulfamethoxazole (TMP/SMX) hypersensitivity is reported in patients with systemic lupus erythematosus (SLE), and reactions are often severe. Desensitization protocol is…
Abstract Number: 636 • 2013 ACR/ARHP Annual Meeting
Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow
Anna Bird¹, Nida Meednu², Javier Rangel-Moreno³, Srilakshmi Yalavarthi⁴, Jennifer Barnard¹, Teresa Owen⁵, Jason S. Knight⁶, Alfred Rabinovich¹, Arumugam Palanichamy², Jane Liesveld⁷, Jason W Bauer⁸, Emily Baechler⁹, Mariana J. Kaplan¹⁰ and Jennifer H. Anolik¹¹, ¹Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴University of Michigan Rheumatology, Ann Arbor, MI, ⁵Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, ⁸University of Minnesota, Minneapolis, MN, ⁹Medicine, University of Minnesota, Minneapolis, MN, ¹⁰Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, ¹¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Although SLE is known to be associated with a type I interferon signature in the peripheral blood, the precise site and mechanism of IFN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].